. Author manuscript; available in PMC: 2016 Sep 15.

Published in final edited form as: Cancer Prev Res (Phila). 2015 Jun 22;8(9):796–806. doi: 10.1158/1940-6207.CAPR-15-0018

Table 3.

Fatty acid derivatives in adipose tissue of non-tumor bearing mice after 6 weeks EPA+DHA supplementation.

Adipose Tissue (ng/mg protein)	Control (n = 3)	Control + EPA+DHA (n = 3)	DIO (n = 3)	DIO + EPA+DHA (n = 3)
6ketoPGF1α	148 ± 58	144 ± 33	211 ± 103	47.6 ± 47
TXB2	6.7 ± 1.5	5.4 ± 2.2	10.0 ± 5.3	4.2 ± 4.2
PGF2α	11.3 ± 3.5	8.7 ± 2.7	22.8 ± 11.0	4.4 ± 3.5
PGE2	35.8 ± 9.9	31.3 ± 6.6	51.4 ± 34.5	9.3 ± 9.2
PGD2	47 ± 22	37 ± 11	199 ± 92	113 ± 106
13HODE	973 ± 456	648 ± 123	1175 ± 268	769 ± 542
15HETE	171 ± 61	85 ± 5	159 ± 39	84 ± 62
12HETE	753 ± 216	400 ± 72	776 ± 158	320 ± 230
5HETE	11.0 ± 1.2	8.6 ± 3.1	15.6 ± 3.7	18.8 ± 12.6
18-HEPE	0.16 ± 0.08^a	2.34 ± 0.44^b	0.79 ± 0.22^b	7.46 ± 6.32^b
PGE3	0.29 ± 0.06^a	3.35 ± 0.94^b	0.73 ± 0.47	1.07 ± 0.60

6-ketoPGF1α, 6-keto prostaglandin F1α; TXB2, thromboxane B2; PGE3, prostaglandin E3; PGF2α, prostaglandin F2α; PGE2, prostaglandin E2; PGD2, prostaglandin D2; 13HODE, 13-hydroxyoctadecadienoic acid; 15HETE, 15-hydroxyeicosatetraenoic acid; 12HETE, 12-hydroxyeicosatetraenoic acid; 5HETE, 5-hydroxyeicosatetraenoic acid; 18HEPE, 18-hydroxyeicosapentaenoic acid. Statistically significant (P≤0.05) differences are indicated by different letters, e.g., a group designated with is ^a different than a group designated with ^b; but two groups with ^b are not different.